// App-Quantinova.ai

POS0086 (2021) : ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

Researchers

Presenter

  • R. Fleischmann

Principal Investigators

  • B. Haraoui

  • M. H. Buch

  • D. Gold

  • H. Shi

  • A. Diehl

  • K. Lee

Medical Centers

  • Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX

  • Institut de Rhumatologie, Montreal, QC, Canada

  • School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom

  • NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Pfizer Inc, Inflammation and Immunology, Kirkland, QC, Canada

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

Drug/Treatment

  • Methotrexate

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02831855

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved